INFI - Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Infinity Pharmaceuticals ([[INFI]] -19.5%) has announced data from the front-line triple negative breast cancer cohort from its ongoing MARIO-3 trial, evaluating eganelisib in combination with atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane). Data were presented at the San Antonio Breast Cancer Symposium.All 13 evaluable patients demonstrated tumor reduction, while overall response rate of 69.2% was observed.One 1 complete response and 4 partial reponses ((PR)) were observed in PD-L1 positive patients and with 4 PRs observed in PD-L1 negative patients.On the safety front, most common severe or higher treatment-emergent adverse events were decreased neutrophil count (21.4%), diarrhea (14.3%), and rash (14.3%).The company expects to complete enrollment in MARIO-3 in mid-2021.

For further details see:

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium